The Shifting Therapeutic Spectrum for Chronic Lymphocytic Leukemia
For patients with chronic lymphocytic leukemia, including those with high-risk disease, the availability of novel targeted therapies and monoclonal antibodies offers an increased potential for improved outcomes.
Chronic Lymphocytic Leukemia: Updates in Diagnosis and Testing
There have been updates in chronic lymphocytic leukemia prevalence and diagnosis, with an emphasis on testing options.
New Directions in Chronic Lymphocytic Leukemia Care: A Review of 2019 Treatment Guideline Updates
In December 2018, pivotal trial data were presented at the ASH Annual Meeting that demonstrated promising results for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia. In particular, new courses of CLL care in several patient populations emerged from the findings of 3 trials.
An Investigator's Perspective on the Chronic Lymphocytic Leukemia Research Front
Jennifer Woyach, MD, discusses the current treatment spectrum of chronic lymphocytic leukemia and the significance of the ALLIANCE trial.
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia
Matthew S. Davids, MD, MMSc, characterizes the significance of the ALLIANCE, ECOG E1912, and iLLUMINATE trials within the broader treatment spectrum for chronic lymphocytic leukemia.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512